Clinical Trials Logo

Filter by:
NCT ID: NCT04829331 Terminated - Wound Heal Clinical Trials

Utility of Restrata With Split Thickness Skin Graft to Reconstruct the Forearm Donor Site

Start date: April 9, 2021
Phase: N/A
Study type: Interventional

Understand association between use of Restrata (Acera Surgical Inc., St. Louis, MO) in forearm flap reconstruction with donor site healing and function

NCT ID: NCT04828161 Terminated - COVID-19 Clinical Trials

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19

EMPATHY
Start date: May 10, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for treating COVID-19 in adult ambulatory patients.

NCT ID: NCT04827485 Terminated - Clinical trials for Colorectal Neoplasms

Gluteal Squeeze for Left Colon Distension

Start date: January 13, 2022
Phase: N/A
Study type: Interventional

Good distension of the colon during colonoscopy is essential to detect polyps. Gas sometimes escapes the colon through the anus resulting in compromised distension. Pressure on gluteal muscles when the colonoscope tip is in the left colon might help preventing this and thus increase visibility. No previous study looked at this.

NCT ID: NCT04826965 Terminated - Clinical trials for Lower Extremity Wound

VAC Bioburden Wound Care Assessment

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the microbiologic burden and need for further operative debridement of patients undergoing primary surgical debridement of infected tissue, soft tissue abscesses, or traumatic wounds of the upper and lower extremity.

NCT ID: NCT04826484 Terminated - Urologic Diseases Clinical Trials

Opioid Reduction Initiative During Outpatient Pediatric Urologic Procedures Using Exparel

Baby ORIOLES
Start date: October 1, 2021
Phase: Phase 3
Study type: Interventional

This study aims to evaluate the utility of long-acting liposomal bupivacaine (Exparel®) in improving pain scores and reducing narcotic pain requirements in pediatric patients following minor urologic procedures.

NCT ID: NCT04826133 Terminated - Clinical trials for Cocaine Use Disorder

Vitamin D and Cocaine Administration

Start date: March 27, 2019
Phase: Early Phase 1
Study type: Interventional

This study is designed to explore the effects of acute pre-treatment with 1,25-dihydroxyvitamin D3 (calcitriol), as compared to placebo on the behavioral (e.g., attempts to self-administer and ultimate number of infusions/boluses of cocaine self-administered), neurocognitive (e.g., performance on computerized tests of reward related learning such as the probabilistic selection task or PST and probabilistic reward task or PRT), and subjective effects (e.g, computerized visual analog scale [VAS] ratings of euphoria/, craving, etc.) of cocaine in experienced, non-treatment seeking users of the drug.

NCT ID: NCT04824859 Terminated - Cancer Clinical Trials

A Geriatric Assessment Electronic Platform for Older Patients With Cancer (eGAP - Electronic Geriatric Assessment Platform)

Start date: December 7, 2021
Phase: N/A
Study type: Interventional

This project assesses the feasibility and usability of the geriatric assessment platform (electronic Geriatric Assessment Platform or eGAP in 50 older patients with cancer, their caregivers, and their oncology team. Using an iterative process, we will refine the eGAP based on input from stakeholders.

NCT ID: NCT04824521 Terminated - Opioid-use Disorder Clinical Trials

A Pilot Feasibility Study of Mindfulness-Oriented Recovery Enhancement With Pregnant Women With Opioid Use Disorder

Start date: October 1, 2021
Phase: N/A
Study type: Interventional

Thirty pregnant women with substance use disorder will be recruited to participate in eight sessions of MORE.

NCT ID: NCT04822701 Terminated - COVID-19 Clinical Trials

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

Start date: April 21, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This study is open to adults with mild to moderate symptoms of COVID-19 (coronavirus disease). The purpose of this study is to find out whether a medicine called BI 767551 helps people with COVID-19. BI 767551 is an antibody against the coronavirus. The study has 2 parts. Part 1 wants to find out the best dose of BI 767551 given as infusion into a vein. It also tests how BI 767551 is taken up by the body when taken via an inhaler. Participants are put into 4 groups by chance. Participants get BI 767551 or placebo once. - 1 group gets a high dose of BI 767551 as an infusion into a vein - 1 group gets a low dose of BI 767551 as an infusion into a vein - 1 group gets BI 767551 via an inhaler - 1 group gets placebo both as an infusion into a vein and via an inhaler The placebo infusion and inhaler look like the BI 767551 infusion and inhaler but do not contain any medicine. Doctors check how BI 767551 reduces the amount of coronavirus. Once the best dose of BI 767551 is found, part 2 of the study tests BI 767551 in a larger group of people. Also, in part 2, the participants get BI 767551 or placebo as an infusion into a vein once. In this part, doctors will check how many people need to be treated in a hospital or die. The results will be compared between the groups. For each part, participants are in the study for about 13 weeks. During this time, they visit the study site about 8 times and get about 3 remote visits. The doctors also regularly check participants' health and take note of any unwanted effects of BI 767551.

NCT ID: NCT04822298 Terminated - Clinical trials for Non-small Cell Lung Cancer

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

Start date: August 31, 2021
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).